S
Stephan R. Targan
Researcher at Cedars-Sinai Medical Center
Publications - 577
Citations - 61849
Stephan R. Targan is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 108, co-authored 545 publications receiving 58069 citations. Previous affiliations of Stephan R. Targan include University of Münster & Mount Sinai Hospital, Toronto.
Papers
More filters
Journal ArticleDOI
Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients.
TL;DR: There are in vivo humoral immune defects in inflammatory bowel disease, and antibody production by the B cells that spontaneously secrete tetanus-specific immunoglobulin G in vitro was highly variable and below normal in the majority of Crohn's disease and ulcerative colitis patients.
Journal ArticleDOI
Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications.
Katherine Facklis,Scott E. Plevy,Eric A. Vasiliauskas,Lori Kam,Kent D. Taylor,Stephan R. Targan,Phillip Fleshner +6 more
TL;DR: The Crohn's disease-associated tumor necrosis factor microsatellite haplotype a2b1c2d4e1 may define a subgroup of medically unresponsive patients with ulcerative colitis who are predisposed to a higher incidence of pouch-specific complications after ileal pouch-anal anastomosis.
Journal ArticleDOI
HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T cell proliferation and TH1/TH17 responses
Kathrin S. Michelsen,Michelle H. Wong,Brian Ko,Lisa S. Thomas,Deepti Dhall,Stephan R. Targan +5 more
TL;DR: HMPL-004 inhibits the development of chronic colitis by affecting early T-cell proliferation, differentiation, and TH1/TH17 responses in a T- cell-driven model of colitis, presenting a unique mechanism of action.
Journal ArticleDOI
Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa.
Konstantinos A. Papadakis,John Prehn,Daocheng Zhu,Carol J. Landers,Joanne Gaiennie,Phillip Fleshner,Stephan R. Targan +6 more
TL;DR: Activation-dependent receptor regulation and alteration in receptor-bearing cells, primarily in MLN draining inflamed intestinal tissue, suggest an important role for this T-cell subset in the pathogenesis of human IBD.
Journal ArticleDOI
Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease.
TL;DR: This is a report of successful and sustained response to anti-CD2O antibody treatment, rituximab, for IBD-associated thrombocytopenia, and suggests that therapies directed against B-lymphocytes may not be effective for the treatment of human IBD, they may possibly be detrimental.